Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Open-Label, Multi-Centre, International Safety Study of Durvalumab Following Sequential Chemotherapy and Radiation Therapy in Patients With Stage III, Unresectable Non-Small Cell Lung Cancer (PACIFIC 6)

NCT03693300 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT03693300
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03693300 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Open-Label, Multi-Centre, International Safety Study of Durvalumab Following Sequential Chemotherapy and Radiation Therapy in Patients With Stage III, Unresectable Non-Small Cell Lung Cancer (PACIFIC 6)
Lead sponsor
AstraZeneca
Phase
Phase 2
Overall status
Completed
Start date
April 16, 2019
Completion date
April 21, 2023
Enrollment
117 (actual)
Sites
28

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung cancer (nsclc)